Invention Grant
- Patent Title: PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof
-
Application No.: US16066567Application Date: 2016-12-20
-
Publication No.: US10793643B2Publication Date: 2020-10-06
- Inventor: Xiangdong Qu , Xin Ye , Shaoyu Xu , Bei Yuan , Dongbing Cui , Qiyue Hu , Lei Zhang , Zhibin Xu , Weikang Tao , Lianshan Zhang , Piaoyang Sun
- Applicant: Jiangsu Hengrui Medicine Co., Ltd. , Shanghai Hengrui Pharmaceutical Co., Ltd.
- Applicant Address: CN Lianyungang, Jiangsu CN Shanghai
- Assignee: Jiangsu Hengrui Medicine Co., Ltd.,Shanghai Hengrui Pharmaceutical Co., Ltd.
- Current Assignee: Jiangsu Hengrui Medicine Co., Ltd.,Shanghai Hengrui Pharmaceutical Co., Ltd.
- Current Assignee Address: CN Lianyungang, Jiangsu CN Shanghai
- Agency: Ice Miller LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@2dad89e4
- International Application: PCT/CN2016/111053 WO 20161220
- International Announcement: WO2017/114230 WO 20170706
- Main IPC: C07K16/40
- IPC: C07K16/40 ; C12N9/64 ; A61K39/395 ; A61P3/06 ; C12N15/62 ; A61K39/00
Abstract:
The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.
Public/Granted literature
- US20190016825A1 PCSK9 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF Public/Granted day:2019-01-17
Information query
